We repurposed a wide range of small molecules that are widely explored for their protein stabilizing ability for treating various genetic disorders from the published literature, which had not been studied for GD, and employed a comprehensive process pipeline for the pre-clinical identification of new glucocerebrosidase stabilizers. The gene discussed is GBA1; the disease is hereditary disease.